Literature DB >> 16872570

Within-subject variation of the salivary 3HC/COT ratio in regular daily smokers: prospects for estimating CYP2A6 enzyme activity in large-scale surveys of nicotine metabolic rate.

Rod A Lea1, Stuart Dickson, Neal L Benowitz.   

Abstract

Nicotine is the major addictive compound in tobacco and is responsible for tobacco dependence. It is primarily metabolized to cotinine (COT) and trans-3'-hydroxycotinine (3HC) by the liver enzyme cytochrome P-450 2A6 (CYP2A6). The 3HC/COT ratio measured in the saliva of smokers is highly correlated with the intrinsic hepatic clearance of nicotine and, therefore, may be a useful non-invasive marker of CYP2A6 activity and metabolic rate of nicotine. This study assessed within-subject variation in salivary 3HC/COT ratios in six regular daily smokers. Our data provide evidence that 1. variation in the 3HC/COT ratio is not dependent on the time of sampling during the day (i.e., morning vs. night ) (P > 0.1) and 2. the average within-subject biological variation in the 3HC/COT ratio is approximately 26%. These findings should be useful for designing large-scale population surveys to assess the variation in the metabolic rate of nicotine (via CYP2A6) in smokers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16872570     DOI: 10.1093/jat/30.6.386

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  46 in total

Review 1.  Alternative Sampling Strategies for Cytochrome P450 Phenotyping.

Authors:  Pieter M M De Kesel; Willy E Lambert; Christophe P Stove
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

Review 2.  Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio.

Authors:  Cheyenne E Allenby; Kelly A Boylan; Caryn Lerman; Mary Falcone
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-12       Impact factor: 4.147

3.  The relationship between the nicotine metabolite ratio and three self-report measures of nicotine dependence across sex and race.

Authors:  Robert A Schnoll; Tony P George; Larry Hawk; Paul Cinciripini; Paul Wileyto; Rachel F Tyndale
Journal:  Psychopharmacology (Berl)       Date:  2014-01-09       Impact factor: 4.530

4.  Nicotine Metabolite Ratio Is Associated With Lozenge Use But Not Quitting in Smokeless Tobacco Users.

Authors:  Jon O Ebbert; Herbert H Severson; Brian G Danaher; Neal L Benowitz; Darrell R Schroeder
Journal:  Nicotine Tob Res       Date:  2015-05-14       Impact factor: 4.244

5.  Nicotine metabolism and addiction among adolescent smokers.

Authors:  Mark L Rubinstein; Saul Shiffman; Anna-Barbara Moscicki; Michelle A Rait; Saunak Sen; Neal L Benowitz
Journal:  Addiction       Date:  2012-10-05       Impact factor: 6.526

6.  Nicotine Metabolism in Young Adult Daily Menthol and Nonmenthol Smokers.

Authors:  Pebbles Fagan; Pallav Pokhrel; Thaddeus A Herzog; Ian S Pagano; Adrian A Franke; Mark S Clanton; Linda A Alexander; Dennis R Trinidad; Kari-Lyn K Sakuma; Carl A Johnson; Eric T Moolchan
Journal:  Nicotine Tob Res       Date:  2015-05-19       Impact factor: 4.244

Review 7.  Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not?

Authors:  Henry R Kranzler; Rachel V Smith; Robert Schnoll; Afaf Moustafa; Emma Greenstreet-Akman
Journal:  Addiction       Date:  2017-04-21       Impact factor: 6.526

Review 8.  Biomarkers for smoking cessation.

Authors:  K J Bough; C Lerman; J E Rose; F J McClernon; P J Kenny; R F Tyndale; S P David; E A Stein; G R Uhl; D V Conti; C Green; S Amur
Journal:  Clin Pharmacol Ther       Date:  2013-03-18       Impact factor: 6.875

9.  Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer.

Authors:  Julie-Anne Tanner; Jeffrey A Henderson; Dedra Buchwald; Barbara V Howard; Patricia Nez Henderson; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2017-05       Impact factor: 2.089

10.  Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers.

Authors:  M K Ho; J C Mwenifumbo; N Al Koudsi; K S Okuyemi; J S Ahluwalia; N L Benowitz; R F Tyndale
Journal:  Clin Pharmacol Ther       Date:  2009-03-11       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.